ClinicalTrials.gg
RecruitingNCT07296887Updated Jul 8, 2026

CARE Tool Study Aim 3

An interventional study of Financial education information and CARE Tool in Gynecologic Cancer, Prostate Cancer and Lung Cancer, sponsored by Washington University School of Medicine. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.

Planned enrollment
3rd of 20
430 · median 35
Started
2026
with 4 others
No phase
12 of 23
4 open now
Primary completion
2028-07
later than 6 of 10 live
Registered
20th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 12 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 20th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients with cancer overcome barriers they face navigating insurance and accessing financial resources.

03

Conditions studied

  • Gynecologic Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colorectal Cancer

Keywords

  • Insurance
  • Insurance coverage
  • Cancer
  • Cost of medical care
  • Financial toxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Implementation champions:

- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients receiving treatment for gynecologic, lung, prostate, or colorectal cancer; or members of the billing team and employee of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital

Exclusion Criteria for Implementation champions:

  • Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
  • Do not treat patients for gynecologic, prostate, lung, or colorectal cancer

Inclusion Criteria for Patients:

  • Age 18 and over
  • Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months
  • Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
  • Self-reported ability to read and speak English

Exclusion Criteria for Patients:

  • Under the age of 18
  • Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment
  • Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
  • Cannot give consent due to cognitive or emotional barriers
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Arm 1: Patients - Care Tool (Intervention)

    Patients will review the web-based CARE Tool after enrollment. Patients will complete a survey immediately after reviewing the website and a 3 month follow-up survey.

    Other: CARE Tool

  • Active comparator
    Arm 2: Patients - Standard of care financial education information (Control)

    Patients will review standard web-based financial education information after enrollment. Patients will complete a survey immediately after reviewing the website and a 3 month follow up survey.

    Other: Financial education information

  • Experimental
    Arm 3: Implementation champions - CARE training

    Participants who are members of the care team and have been identified as implementation champions will complete training on the CARE Tool and cost conversations. Participants will complete a survey after the training and a post-recruitment survey at the end of the trial.

    Other: CARE Tool Training

Interventions

  • OtherFinancial education information

    Standard financial education resources will be provided to patients enrolled in the control arm. Financial education will be accessible via website and provided by the participating site.

  • OtherCARE Tool

    The CARE Tool is a web-based tool provided to patients after enrollment. The CARE Tool provides patients with individualized information about cancer care costs, health insurance, and resources to assist with costs.

  • OtherCARE Tool Training

    Members of the care team who have been identified as implementation champions will undergo training on cost conversations, how to use the CARE Tool, and how to implement the CARE Tool in their clinical workflow.

06

What researchers measure

Primary outcomes

  1. Patient's comprehensive score for financial toxicity (COST)

    COST will be calculated by the sum of 11-items according to the validated measure. The items are scored on a 5-point Likert scale as follows: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, and 4-Very much. Total possible range is 0-44 and the lower the score indicates greater financial toxicity. Scores will be summarized using means and 95% confidence intervals. Changes between timepoints will be analyzed by a two-sample t-test.

    Time frame: Completion of initial survey to completion of follow up survey (total estimated time is 3 months)

  2. Patient's score of self-efficacy for communicating about care costs measured with the Decision Self-Efficacy Scale

    The measure of self-efficacy for communicating about care costs is adapted from the validated tool Decision Self-Efficacy Scale. The Decision Self-Efficacy Scale measures self-confidence or belief in one's abilities in decision making, including shared decision making. Three-items from the Decision Self-Efficacy Scale will be used to measure self-efficacy for communicating about care costs. The three items will be measured by a 3-point Likert scale as follows: 0-Not Confident, 2-A Little Confident, and 4-A lot confident. A higher score indicates greater self-efficacy in decision making. The total score will be calculated according to the validated measure. Scores will be summarized using means and 95% confidence intervals. Changes between timepoints will be analyzed by a two-sample t-test.

    Time frame: Completion of initial survey to completion of follow up survey (total estimated time is 3 months)

  3. Patient's health insurance literacy measure (HILM) score

    HILM score is calculated from a 6-item questionnaire according to the validated measure. Each item is measured by a 4-point Likert scale as follows: 1-Not at all confident, 2-Slightly confident, 3-Moderately confident, and 4-Very confident. Total possible range is 0-100 where 0 represents the lowest possible health insurance literacy level (more difficulty navigating insurance) and 100 represents the highest (more confidence in choosing/using insurance). Scores will be summarized using means and 95% confidence intervals. Changes between timepoints will be analyzed by a two-sample t-test.

    Time frame: Completion of initial survey to completion of follow up survey (total estimated time is 3 months)

Secondary outcomes

  1. Patient's reported adherence to therapy & delayed care

    Patient reported delayed care will be calculated from responses to three-items adapted from the National Health Interview Survey (NHIS). The three items have four categorical answers: Yes, No, I don't know, and Prefer not to answer. Scores will be summarized using frequencies. Changes between timepoints will be analyzed using sample proportions and 95% Clopper-Pearson Confidence Intervals. Changes between timepoints will be analyzed by a Pearson Chi-square test. .

    Time frame: Completion of initial survey to completion of follow up survey (total estimated time is 3 months)

  2. Feasibility of Intervention Measure (FIM) - Adapted

    FIM will be assessed by implementation champions' response to a single item from the FIM measure on the initial and follow up survey. FIM is measured by a 5-point Likert scale: 1-Completely disagree, 2-Disagree, 3-Neither agree nor Disagree, 4-Agree, or 5-Completely agree. A higher score indicates greater feasibility of the intervention in practice. Outcome will be summarized using means and 95% confidence intervals. Changes between surveys will be analyzed by a two-sample t-test.

    Time frame: At start of recruitment and at completion recruitment (total estimated time is 2 years)

  3. Acceptability of Intervention Measure (AIM) - Adapted

    AIM will be assessed by implementation champions' response to a single item from the AIM measure on the initial and follow up survey. AIM is measured by a 5-point Likert scale: 1-Completely disagree, 2-Disagree, 3-Neither agree nor Disagree, 4-Agree, or 5-Completely agree. A higher score indicates greater acceptability by subjects of the intervention. Outcome will be summarized using means and 95% confidence intervals. Changes between surveys will be analyzed by a two-sample t-test.

    Time frame: At start of recruitment and at completion recruitment (total estimated time is 2 years)

  4. Intervention Appropriateness Measure (IAM) - Adapted

    IAM will be assessed by implementation champions' response to a single item from the IAM measure on the initial and follow up survey. IAM is measured by a 5-point Likert scale: 1-Completely disagree, 2-Disagree, 3-Neither agree nor Disagree, 4-Agree, or 5-Completely agree. A higher score indicates greater appropriateness of the intervention. Outcome will be summarized using means and 95% confidence intervals. Changes between surveys will be analyzed by a two-sample t-test.

    Time frame: At start of recruitment and at completion recruitment (total estimated time is 2 years)

Other outcomes

  1. Organizational Readiness-Adapted

    Organizational readiness will be assessed by implementation champions' response to 6 items adapted from the MORE measure for organizational readiness and 3 items adapted from the organizational readiness for implementing change (ORIC) measure. MORE items are measured on a 4-point Likert scale: 1-Not willing, 2-Somewhat willing, 3-Willing, and 4-Very willing. A higher score indicates greater organizational readiness. ORIC items are measured on a 5-point Likert scale: 1-Disagree, 2-Somewhat Disagree, 3-Neither agree nor Disagree, 4-Somewhat Agree, or 5-Agree. A higher score indicates greater organizational readiness to implement change. Changes between surveys will be analyzed by a two-sample t-test.

    Time frame: At start of recruitment and at completion recruitment (total estimated time is 2 years)

07

Study locations

3 of 3 sites recruiting
  • Alton Memorial Hospital
    Alton, Illinois 62002, United States
    Recruiting
    • Ashley Housten, OTD, MSCI, OTR/L · Contactahousten@wustl.edu · 314-454-7958
    • Ashley Housten, OTD, MSCI, OTR/L · Principal investigator
  • Delbert Day Cancer Institute at Phelps Health
    Rolla, Missouri 65401, United States
    Recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Ashley Housten, OTD, MSCI, OTR/L · Contactahousten@wustl.edu · 314-454-7958
    • Krista Cooksey, BA · Contactkcooksey@wustl.edu · 314-935-7234
    • Ashley Housten, OTD, MSCI, OTR/L · Principal investigator
    • Su-Hsin Chang, PhD · Sub investigator
    • Mary Politi, PhD · Sub investigator
    • Aimee James, PhD, MPH · Sub investigator
    • Esther Lu, MS, PhD · Sub investigator
    • Jennifer Irvin, MHSA, CHW-C · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Participants can share their data for future research. Data such as age, sex, gender identity, race, and ethnicity, will be redacted to strip identifiers and minimize risks of unauthorized disclosure of personal identifiers. Common data elements (CDEs), identified by NCI and the ACCERT sites, will include identifiable information like zip code and county. Data from this optional survey could identify participants and may be shared with the NCI and ACCERT study teams . Publicly available documentation will include the study protocol, survey questions, codebook, univariate statistics, and study-level metadata. The codebook will include a description of each variable with the question number and text, variable name, variable label, value labels, and standard codes for missing values-including codes for non-applicable, "don't know," or prefer not to answer. We may share algorithms produced for analysis of CDEs. Users must agree to the conditions of use governing access to the data.

Supporting information: Study protocol

Time frame: Final submission and deposit of the study data will occur at the end of data collection. Study data deposited will be available to the research community in perpetuity. Datasets underlying methodological publications will be shared at or prior to initial publication date.

Access criteria: Researchers within the ACCERT consortium and those who provide a methodologically sound plan.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 27 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Dec 22, 2025
StartActual
Apr 8, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07296887
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Apr 8, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Ashley Housten, OTD, MSCI, OTR/L
Contact
ahousten@wustl.edu
314-454-7958
Krista Cooksey, BA
Contact
kcooksey@wustl.edu
314-935-7234
Ashley Housten, OTD, MSCI, OTR/L
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion